Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Sarepta therapeutics - What They Never Told You

Late Stage Trial Miss Leaves Adults with Myotonic Dystrophy Still Waiting for a First Approved Treatment

Novartis says its Phase 3 HARBOR trial of del-desiran missed its main goal in myotonic dystrophy type 1, a disease with no approved therapy.

Medical Daily

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

The U.S. Food and Drug Administration (FDA) on Tuesday approved dosing in Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) Cohort 8 of ENDEAVOR (Study 9001-103).

Benzinga

What's Going On Sarepta Stock On Wednesday?

Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading higher on Wednesday, with apparently no news to justify the movement.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga

Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside

Per two Wall Street analysts, one of 2025's biggest losers could be set up for a stunning recovery. They see over 175% upside in Sarepta Therapeutics.

MarketBeat

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Recent developments with Sarepta Therapeutics Inc (NASDAQ:SRPT) highlight the delicate balance between innovation and patient safety in the biopharmaceutical industry.

Benzinga

This Sarepta Therapeutics Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?

Stock of Sarepta Therapeutics Inc. (NASDAQ:SRPT) surged 41.05% in Tuesday pre-market following the U.S. Food and Drug Administration’s (FDA) recommendation to lift the voluntary hold on Elevidys, Sarepta’s gene therapy for Duchenne Muscular Dystrophy.

Benzinga

BitMine Immersion, Sarepta Therapeutics, CEA Industries, Super Micro Computer And AMD: Why These 5 Stocks Are On Investors' Radars Today

U.S. markets closed mixed on Monday, with the Dow Jones Industrial Average slipping 0.1% to 44,837.56 and the SP 500 holding steady at 6,389.77. The Nasdaq edged up 0.3% to finish at 21,178.58.

Benzinga

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy

The Independent UK

Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares were halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.

Benzinga

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an 8-year-old boy who had received Elevidys, Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) gene therapy for Duchenne muscular dystrophy.

Benzinga

This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Benzinga

Elevidys Halt Sparks Analyst Downgrades—Sarepta Races To Revise Label

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced Monday it will voluntarily and temporarily pause all U.S. shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, effective July 22.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that have attracted attention from regulators

Benzinga

Sarepta Reverses Course, Pauses Elevidys Shipments Amid FDA Safety Review

Benzinga

Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets

On Friday, the U.S. Food and Drug Administration placed Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on a clinical hold.

Benzinga

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene therapy

Benzinga

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Sarepta Therapeutics (NASDAQ:SRPT) shares plummeted on Friday following reports of a third patient death linked to its gene therapy pipeline this year, further clouding investor confidence despite the company’s recent efforts to provide clarity on its restructuring and FDA label plans.

Benzinga

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On

Shares of Sarepta Therapeutics (NASDAQ:SRPT) plunged over 30% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to the company’s experimental treatments.

Benzinga

Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in pre-market trading after the company announced it will engage in strategic restructuring and cost savings.

Benzinga

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a strategic restructuring and cost-cutting measures.

Benzinga

Palantir Co-Founder Joe Lonsdale Wants A FDA Overhaul With Special Forces-Style AI Team Because China Is Racing To Outpace US In Biotech

On Monday, Palantir Technologies Inc. (NASDAQ:PLTR) co-founder Joe Lonsdale urged a tech-driven transformation of the Food and Drug Administration, warning that bureaucratic inertia is putting the U.S. behind China in the biotech race.

Benzinga

This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Palantir Technologies Inc

236 stories

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Disease

16,644 stories

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.